Mutation profile of colon cancer in hispanic population of central California.

e16067 Background: The clinical and mutational profile of Hispanic patients with metastatic colon cancer is not well documented. In this retrospective study, we aim to describe the clinical and mutational profile of Hispanic patients with metastatic colon cancer in central California. Methods: We retrospectively evaluated the clinical and mutational profile of colon cancer at a single institution in Fresno, California from 2010-2019. We selected 136 patients out of which 70 patients self-identified as Hispanic and 66 self-identified as non-Hispanic. We studied clinical parameters and next-generation sequencing via Foundation one testing for these patients. Results: Among Hispanics, there were 43(61%) males and 27(38%) females. The median age at diagnosis was similar in both groups at 57. Right sided colon cancer accounted for 52% of Hispanic patients versus 40% in non-Hispanics. Fifty two percent of Hispanic patients presented with metastatic disease versus 45% in non-Hispanics. The frequency of commonly mutated genes in colon cancer in Hispanics versus non-Hispanics are as follows. KRAS (35.7% vs 37%), NRAS (11% vs 4%) BRAF (8% vs 7%), Her2/neu 0% in both groups. The frequency of other mutations such as TP53, APC, ATM, PTEN, CDKN2A, Myc amplification were also noted to be similar in both groups. PIK3CA mutation was seen in 18.6% of Hispanic patients versus 34% in non-Hispanic population which was statistically significant with a p value = 0.032. Microsatellite instability (MSI) was seen at 3.3% in Hispanics versus 10.6% in non-Hispanics. Tumor mutational burden was similar in both groups. Conclusions: The frequency of actionable mutations was similar in both Hispanic and non-Hispanic patients. Hispanics were noted to have lower PIK3CA and microsatellite instability. Metastatic disease and right sided colon cancer were seen at higher frequency in Hispanic population. Our results were similar to another population-based study which analyzed KRAS mutation with colon cancer patients in Puerto Rico[1]. Larger population based studies would be needed to further assess the differences in this patient population. Ruiz-Candelaria, Y., C. Miranda-Diaz, and R.F. Hunter-Mellado, K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. Int J Biol Markers, 2013. 28(4): p. e393-7.

Download Full-text

Chemotherapy of metastatic colon cancer in France: A population-based study

Digestive and Liver Disease ◽

10.1016/j.dld.2021.03.019 ◽

2021 ◽

Author(s):

Léo Mas ◽

Jean-Baptiste Bachet ◽

Valérie Jooste ◽

Côme Lepage ◽

Anne-Marie Bouvier

Keyword(s):

Colon Cancer ◽

Population Based ◽

Metastatic Colon Cancer ◽

Population Based Study

Download Full-text

Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study

Internal and Emergency Medicine ◽

10.1007/s11739-015-1285-6 ◽

2015 ◽

Vol 11 (1) ◽

pp. 41-46 ◽

Cited By ~ 1

Author(s):

Francesco Iachetta ◽

Federica Domati ◽

Luca Reggiani-Bonetti ◽

Valeria Barresi ◽

Giulia Magnani ◽

...

Keyword(s):

Colon Cancer ◽

Microsatellite Instability ◽

Population Based ◽

Population Based Study ◽

Prognostic Relevance

Download Full-text

Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series

Histopathology ◽

10.1111/his.14233 ◽

2020 ◽

Cited By ~ 2

Author(s):

Maurice B Loughrey ◽

Jason McGrath ◽

Helen G Coleman ◽

Peter Bankhead ◽

Perry Maxwell ◽

...

Keyword(s):

Colon Cancer ◽

Microsatellite Instability ◽

Mismatch Repair ◽

Large Population ◽

Population Based

Download Full-text

Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome

Journal of Gastrointestinal Oncology ◽

10.21037/jgo.2018.09.19 ◽

2018 ◽

Vol 10 (1) ◽

pp. 161-165 ◽

Cited By ~ 2

Author(s):

Chongkai Wang ◽

Jaideep Sandhu ◽

Marwan Fakih

Keyword(s):

Colon Cancer ◽

Microsatellite Instability ◽

Complete Response ◽

Guillain Barre Syndrome ◽

Metastatic Colon Cancer ◽

Guillain Barré Syndrome ◽

History Of ◽

Guillain Barré

Download Full-text

The remarkable complete response and improvement of performance status to pembrolizumab of a recurrent microsatellite instability high, metastatic colon cancer, previously treated with Cetuximab, FOLFOX and Irinotecan

Annals of Oncology ◽

10.1093/annonc/mdx511.018 ◽

2017 ◽

Vol 28 ◽

pp. vii19

Author(s):

K. Oracion

Keyword(s):

Colon Cancer ◽

Microsatellite Instability ◽

Performance Status ◽

Complete Response ◽

Metastatic Colon Cancer ◽

Previously Treated

Download Full-text

Real-world treatment patterns and the uptake of biologics in elderly medicare patients with metastatic colon cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.3_suppl.540 ◽

2015 ◽

Vol 33 (3_suppl) ◽

pp. 540-540

Author(s):

C. Daniel Mullins ◽

Kaloyan A. Bikov ◽

Brian S. Seal ◽

Anna Hung ◽

Nader Hanna

Keyword(s):

Colon Cancer ◽

Clinical Practice ◽

Real World ◽

Practice Patterns ◽

Population Based ◽

Metastatic Colon Cancer ◽

Clinical Practice Patterns ◽

Medicare Patients ◽

Number Of Treatment ◽

Cancer Network

540 Background: Metastatic colon cancer (mCC) patients may receive multiple lines of treatment (Tx1, Tx2, etc.) consisting of one or more cytotoxic (CYT: 5FU/LV, oxaliplatin [OX], irinotecan [IRI]) and biologic (BIO: bevacizumab [BEV], cetuximab [CET], panitumumab [PAN]) drugs. The National Comprehensive Cancer Network (NCCN) provides evidence-based Tx recommendations for each line. The objective of this study was to examine real-world clinical practice patterns between 2002 and 2010. In particular, we compared the most common regimens across Tx lines and how Tx patterns changed over time. We also documented the uptake and use of new BIOs. Methods: We used population-based SEER-Medicare data to determine Tx1, Tx2, and Tx3 regimens of 4,616 mCC patients (the median age at diagnosis was 78) diagnosed in 2003-2009 and followed through 2010. We will use an algorithm previously developed by us to identify regimens. Results: The most common CYT backbone in Tx1 was OX (51% of patients) followed by 5FU/LV (30%). In comparison, IRI was a preferred choice in Tx2 (65%) and Tx3 (31%). In 2003, the most common Tx1 regimens were 5FU/LV- (56%) and IRI-based (35%). 5FU/LV and IRI use decreased to 22% and 9% respectively in 2009, while OX use increased from 7% in 2003 to 63% in 2009. In 2004, the FDA approved BEV for Tx1. BEV’s share increased from 9% in 2004 to 53% in 2005. BEV was used in 9% of Tx2 regimens in 2004 and 46% in 2005. CET was approved in 2004. CET was used in less than 5% of Tx1 regimens in any year up to 2010. CET use in Tx2 increased from 19% to 27% between 2005 and 2007, and declined to 23% in 2010. The FDA approved PAN in September 2006 for treatment after failure of CYT-based regimens, i.e., primarily in Tx3 and beyond. Only 350 (8%) of patients received Tx3, and of these 59 (17%) received PAN without a CYT backbone. One in three Tx3 regimens consisted of biologics only (54% CET, 43% PAN). Conclusions: This study used SEER-Medicare registry data to examine and document real-world clinical practice patterns in treatment of elderly mCC patients between 2003 and 2010. We observed that as new biologic agents were introduced to the market, variations in the combinations and the number of treatment have significantly and rapidly changed.

Download Full-text

Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.3_suppl.753 ◽

2015 ◽

Vol 33 (3_suppl) ◽

pp. 753-753

Author(s):

Renata D'Alpino Peixoto ◽

Aalok Kumar ◽

Sharlene Gill ◽

Howard John Lim

Keyword(s):

Colon Cancer ◽

Progression Free Survival ◽

Population Based ◽

Stage Iii ◽

Metastatic Colon Cancer ◽

Stage Iii Colon Cancer ◽

Metastatic Setting ◽

Cancer Agency ◽

Third Line

753 Background: Little is known regarding the efficacy of oxaliplatin-based chemotherapy for metastatic colon cancer patients who have already received adjuvant oxaliplatin-based chemotherapy. Methods: We retrospectively reviewed 22 consecutive patients who developed recurrence after adjuvant oxaliplatin-based chemotherapy for stage III colon cancer and received another course of oxaliplatin-based chemotherapy for their metastatic disease. The main endpoint was progression-free survival (PFS). Results: 635 patients received oxaliplatin-based chemotherapy for stage III colon cancer at the British Columbia Cancer Agency from 2006 to 2011. 176 pts recurred, 22 (12.5%) of whom were re-exposed to oxaliplatin in the metastatic scenario. Oxaliplatin in combination with fluoropyrimidine was given as first line in 3 pts (13.6%), as second line in 14 (63.6%), and third line in 5 (22.7%). Median time from the last cycle of adjuvant oxaliplatin-based chemotherapy to the first cycle of palliative oxaliplatin-based chemotherapy was 44.3 months. Median PFS and OS were 3.3 (95% CI 1.4-5.1) and 10.0 months (95% CI 5.3-14.6), respectively. There was no difference in PFS for patients who were re-exposed to oxaliplatin in less than 36 months or later than that (3.6 versus 3.1 months, p=0.793, HR=0.88). Conclusions: In this population-based study, only a small proportion of pts who recurred after oxaliplatin-based adjuvant therapy received oxaliplatin in the metastatic setting. Re-exposure of oxaliplatin in combination with fluoropyrimidine is associated with only modest PFS benefit. Larger studies evaluating the role of oxaliplatin re-exposure are needed.

Download Full-text